A phase II multicenter trial of hyperCVAD MTX/Ara-C and rituximab in patients with previously untreated mantle cell lymphoma; SWOG 0213

S. H. Bernstein, E. Epner, J. M. Unger, M. LeBlanc, E. Cebula, R. Burack, Lisa M Rimsza, Thomas P Miller, R. I. Fisher

Research output: Contribution to journalArticle

74 Citations (Scopus)

Abstract

Background: Rituximab-hyper-CVAD alternating with rituximab-high-dose methotrexate and cytarabine is a commonly utilized regimen in the United States for mantle cell lymphoma (MCL) based on phase II single institutional data. To confirm the clinical efficacy of this regimen and determine its feasibility in a multicenter study that includes both academic and community-based practices, a phase II study of this regimen was conducted by SWOG. Patients and methods: Forty-nine patients with advanced stage, previously untreated MCL were eligible. The median age was 57.4 years (35-69.8 years). Results: Nineteen patients (39%) did not complete the full scheduled course of treatment due to toxicity. There was one treatment-related death and two cases of secondary myelodysplastic syndrome (MDS). There were 10 episodes of grade 3 febrile neutropenia, 19 episodes of grade 3 and 1 episode of grade 4 infection. With a median follow-up of 4.8 years, the median progression-free survival was 4.8 years (5.5 years for those ≤65 years) and the median overall survival (OS) was 6.8 years. Conclusions: Although this regimen is toxic, it is active for patients ≤65 years of age and can be given both at academic centers and in experienced community centers.

Original languageEnglish (US)
Pages (from-to)1587-1593
Number of pages7
JournalAnnals of Oncology
Volume24
Issue number6
DOIs
StatePublished - Jun 2013

Fingerprint

Mantle-Cell Lymphoma
Cytarabine
Multicenter Studies
Febrile Neutropenia
Poisons
Myelodysplastic Syndromes
Methotrexate
Disease-Free Survival
Survival
Rituximab
Therapeutics
Infection

Keywords

  • Dose-intensive
  • Mantle cell
  • Rituximab

ASJC Scopus subject areas

  • Oncology
  • Hematology

Cite this

Bernstein, S. H., Epner, E., Unger, J. M., LeBlanc, M., Cebula, E., Burack, R., ... Fisher, R. I. (2013). A phase II multicenter trial of hyperCVAD MTX/Ara-C and rituximab in patients with previously untreated mantle cell lymphoma; SWOG 0213. Annals of Oncology, 24(6), 1587-1593. https://doi.org/10.1093/annonc/mdt070

A phase II multicenter trial of hyperCVAD MTX/Ara-C and rituximab in patients with previously untreated mantle cell lymphoma; SWOG 0213. / Bernstein, S. H.; Epner, E.; Unger, J. M.; LeBlanc, M.; Cebula, E.; Burack, R.; Rimsza, Lisa M; Miller, Thomas P; Fisher, R. I.

In: Annals of Oncology, Vol. 24, No. 6, 06.2013, p. 1587-1593.

Research output: Contribution to journalArticle

Bernstein, S. H. ; Epner, E. ; Unger, J. M. ; LeBlanc, M. ; Cebula, E. ; Burack, R. ; Rimsza, Lisa M ; Miller, Thomas P ; Fisher, R. I. / A phase II multicenter trial of hyperCVAD MTX/Ara-C and rituximab in patients with previously untreated mantle cell lymphoma; SWOG 0213. In: Annals of Oncology. 2013 ; Vol. 24, No. 6. pp. 1587-1593.
@article{8845f543a836406d8fd08f9d959f95d9,
title = "A phase II multicenter trial of hyperCVAD MTX/Ara-C and rituximab in patients with previously untreated mantle cell lymphoma; SWOG 0213",
abstract = "Background: Rituximab-hyper-CVAD alternating with rituximab-high-dose methotrexate and cytarabine is a commonly utilized regimen in the United States for mantle cell lymphoma (MCL) based on phase II single institutional data. To confirm the clinical efficacy of this regimen and determine its feasibility in a multicenter study that includes both academic and community-based practices, a phase II study of this regimen was conducted by SWOG. Patients and methods: Forty-nine patients with advanced stage, previously untreated MCL were eligible. The median age was 57.4 years (35-69.8 years). Results: Nineteen patients (39{\%}) did not complete the full scheduled course of treatment due to toxicity. There was one treatment-related death and two cases of secondary myelodysplastic syndrome (MDS). There were 10 episodes of grade 3 febrile neutropenia, 19 episodes of grade 3 and 1 episode of grade 4 infection. With a median follow-up of 4.8 years, the median progression-free survival was 4.8 years (5.5 years for those ≤65 years) and the median overall survival (OS) was 6.8 years. Conclusions: Although this regimen is toxic, it is active for patients ≤65 years of age and can be given both at academic centers and in experienced community centers.",
keywords = "Dose-intensive, Mantle cell, Rituximab",
author = "Bernstein, {S. H.} and E. Epner and Unger, {J. M.} and M. LeBlanc and E. Cebula and R. Burack and Rimsza, {Lisa M} and Miller, {Thomas P} and Fisher, {R. I.}",
year = "2013",
month = "6",
doi = "10.1093/annonc/mdt070",
language = "English (US)",
volume = "24",
pages = "1587--1593",
journal = "Annals of Oncology",
issn = "0923-7534",
publisher = "Oxford University Press",
number = "6",

}

TY - JOUR

T1 - A phase II multicenter trial of hyperCVAD MTX/Ara-C and rituximab in patients with previously untreated mantle cell lymphoma; SWOG 0213

AU - Bernstein, S. H.

AU - Epner, E.

AU - Unger, J. M.

AU - LeBlanc, M.

AU - Cebula, E.

AU - Burack, R.

AU - Rimsza, Lisa M

AU - Miller, Thomas P

AU - Fisher, R. I.

PY - 2013/6

Y1 - 2013/6

N2 - Background: Rituximab-hyper-CVAD alternating with rituximab-high-dose methotrexate and cytarabine is a commonly utilized regimen in the United States for mantle cell lymphoma (MCL) based on phase II single institutional data. To confirm the clinical efficacy of this regimen and determine its feasibility in a multicenter study that includes both academic and community-based practices, a phase II study of this regimen was conducted by SWOG. Patients and methods: Forty-nine patients with advanced stage, previously untreated MCL were eligible. The median age was 57.4 years (35-69.8 years). Results: Nineteen patients (39%) did not complete the full scheduled course of treatment due to toxicity. There was one treatment-related death and two cases of secondary myelodysplastic syndrome (MDS). There were 10 episodes of grade 3 febrile neutropenia, 19 episodes of grade 3 and 1 episode of grade 4 infection. With a median follow-up of 4.8 years, the median progression-free survival was 4.8 years (5.5 years for those ≤65 years) and the median overall survival (OS) was 6.8 years. Conclusions: Although this regimen is toxic, it is active for patients ≤65 years of age and can be given both at academic centers and in experienced community centers.

AB - Background: Rituximab-hyper-CVAD alternating with rituximab-high-dose methotrexate and cytarabine is a commonly utilized regimen in the United States for mantle cell lymphoma (MCL) based on phase II single institutional data. To confirm the clinical efficacy of this regimen and determine its feasibility in a multicenter study that includes both academic and community-based practices, a phase II study of this regimen was conducted by SWOG. Patients and methods: Forty-nine patients with advanced stage, previously untreated MCL were eligible. The median age was 57.4 years (35-69.8 years). Results: Nineteen patients (39%) did not complete the full scheduled course of treatment due to toxicity. There was one treatment-related death and two cases of secondary myelodysplastic syndrome (MDS). There were 10 episodes of grade 3 febrile neutropenia, 19 episodes of grade 3 and 1 episode of grade 4 infection. With a median follow-up of 4.8 years, the median progression-free survival was 4.8 years (5.5 years for those ≤65 years) and the median overall survival (OS) was 6.8 years. Conclusions: Although this regimen is toxic, it is active for patients ≤65 years of age and can be given both at academic centers and in experienced community centers.

KW - Dose-intensive

KW - Mantle cell

KW - Rituximab

UR - http://www.scopus.com/inward/record.url?scp=84878457954&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84878457954&partnerID=8YFLogxK

U2 - 10.1093/annonc/mdt070

DO - 10.1093/annonc/mdt070

M3 - Article

C2 - 23504948

AN - SCOPUS:84878457954

VL - 24

SP - 1587

EP - 1593

JO - Annals of Oncology

JF - Annals of Oncology

SN - 0923-7534

IS - 6

ER -